Xunuo Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xunuo Chen has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Zhe Dai
Department of Endocrinology, Zhongnan Hospital of Wuhan University
3 shared publications Fang Liu
Zhongnan Hospital of Wuhan University
2 shared publicationsHuawei Wang
Zhongnan Hospital of Wuhan University
2 shared publicationsJiawei Chen
Zhongnan Hospital of Wuhan University
2 shared publicationsJun Tang
Zhongnan Hospital of Wuhan University
2 shared publicationsMengyun Lei
Zhongnan Hospital of Wuhan University
2 shared publications
Latest Publications
- Open Access
- 21 September 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (9) , e0343078
Efficacy, safety, and feasibility of youth-derived fecal microbiota transplantation among adults with type 1 diabetes mellitus: A protocol of Pilot Randomized Controlled Trial
Background: Dysbiosis of gut microbiota plays a key role in type 1 diabetes mellitus (T1DM). Fecal microbiota transplantation represents a novel therapeutic avenue. We hypothesize that youth-derived fecal microbiota transplantation (yFMT) can remodel the gut microecosystem and improve clinical outcomes. This pilot trial aims to assess the feasibility, safety, and preliminary efficacy of yFMT in adults with T1DM. Methods and analysis: This single-center, randomized, double-blind, placebo-controlled pilot study will enroll adults with T1DM who have suboptimal glycemic outcomes (glycated hemoglobin [HbA1c] of 7.0–14.0% or time in range [TIR] 70% and time below range <4% at 12 weeks post-randomization. Secondary efficacy endpoints include: (1) the change from baseline in the same composite achievement rate at 4 weeks post-intervention; (2) changes from baseline at Weeks 4 and 12 in other glycemic metrics (including HbA1c, fasting plasma glucose, 2-hour postprandial glucose, and additional CGM metrics), C-peptide, immune responses, infection markers, and gut microbiota composition; and (3) changes from baseline at Week 12 in serum metabolomic profiles (bile acids, short-chain fatty acids, and other related metabolites). Feasibility will be assessed through recruitment rate, retention rate, intervention adherence, and acceptability. Safety endpoints include the incidence of adverse events and serious adverse events. Discussion: Our findings will offer new insight into the feasibility and effects of oral yFMT capsules in adults with T1DM and provide the necessary evidence to power a subsequent multicenter large-scale study. Exploratory biomarker analyses conducted within this study may further pave the way for future individualized microbiome‑based therapeutics. Trial registration: Chinese Clinical Trial Registry identifier: ChiCTR2500111955 (November 7, 2025).
- 21 September 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (9) , e0343078
Open AccessEfficacy, safety, and feasibility of youth-derived fecal microbiota transplantation among adults with type 1 diabetes mellitus: A protocol of Pilot Randomized Controlled Trial
Background: Dysbiosis of gut microbiota plays a key role in type 1 diabetes mellitus (T1DM). Fecal microbiota transplantation represents a novel therapeutic avenue. We hypothesize that youth-derived fecal microbiota transplantation (yFMT) can remodel the gut microecosystem and improve clinical outcomes. This pilot trial aims to assess the feasibility, safety, and preliminary efficacy of yFMT in adults with T1DM. Methods and analysis: This single-center, randomized, double-blind, placebo-controlled pilot study will enroll adults with T1DM who have suboptimal glycemic outcomes (glycated hemoglobin [HbA1c] of 7.0–14.0% or time in range [TIR] 70% and time below range <4% at 12 weeks post-randomization. Secondary efficacy endpoints include: (1) the change from baseline in the same composite achievement rate at 4 weeks post-intervention; (2) changes from baseline at Weeks 4 and 12 in other glycemic metrics (including HbA1c, fasting plasma glucose, 2-hour postprandial glucose, and additional CGM metrics), C-peptide, immune responses, infection markers, and gut microbiota composition; and (3) changes from baseline at Week 12 in serum metabolomic profiles (bile acids, short-chain fatty acids, and other related metabolites). Feasibility will be assessed through recruitment rate, retention rate, intervention adherence, and acceptability. Safety endpoints include the incidence of adverse events and serious adverse events. Discussion: Our findings will offer new insight into the feasibility and effects of oral yFMT capsules in adults with T1DM and provide the necessary evidence to power a subsequent multicenter large-scale study. Exploratory biomarker analyses conducted within this study may further pave the way for future individualized microbiome‑based therapeutics. Trial registration: Chinese Clinical Trial Registry identifier: ChiCTR2500111955 (November 7, 2025).
- Open Access
Efficacy and safety of Youth-derived Fecal Microbiota Transplantation among adults with Type 1 Diabetes Mellitus: A protocol of pilot randomized controlled trial
Background: Dysbiosis of gut microbiota plays a key role in type 1 diabetes mellitus (T1DM). Fecal microbiota transplantation represents a novel therapeutic avenue. We hypothesize that youth-derived fecal microbiota transplantation (yFMT) can remodel the gut microecosystem and improve clinical outcomes. This study aims to investigate the efficacy and safety of orally administered yFMT capsules in adults with T1DM. Methods and analysis: This single-center, randomized, double-blind, placebo-controlled pilot study will enroll adults with T1DM who have suboptimal glycemic outcomes (glycated hemoglobin[HbA1c] of 7-14% and time in range [TIR] 70% and time below range<4% at 4 and 12 weeks post-randomization. Secondary efficacy endpoints comprise changes from baseline at weeks 4 and 12 in other glycemic metrics (including HbA1c, fasting glucose, 2-hour postprandial glucose, and additional CGM metrics), C-peptide, immune responses, infection markers, and gut microbiota composition. Changes from baseline at week 12 in serum metabolomic profiles will also be assessed, encompassing bile acids, short-chain fatty acids, and other related metabolites. Safety endpoints include the incidence of adverse events and serious adverse events. Discussion: Our findings will offer new insight into the feasibility and effects of oral yFMT in adult with T1DM and provide the necessary evidence to power a subsequent multicenter large-scale study. Exploratory biomarker analyses conducted within this study may further pave the way for future individualized microbiome–based therapeutics. Trial registration: Chinese Clinical Trial Registry identifier: ChiCTR2500111955 (November 7, 2025).
Open AccessEfficacy and safety of Youth-derived Fecal Microbiota Transplantation among adults with Type 1 Diabetes Mellitus: A protocol of pilot randomized controlled trial
Background: Dysbiosis of gut microbiota plays a key role in type 1 diabetes mellitus (T1DM). Fecal microbiota transplantation represents a novel therapeutic avenue. We hypothesize that youth-derived fecal microbiota transplantation (yFMT) can remodel the gut microecosystem and improve clinical outcomes. This study aims to investigate the efficacy and safety of orally administered yFMT capsules in adults with T1DM. Methods and analysis: This single-center, randomized, double-blind, placebo-controlled pilot study will enroll adults with T1DM who have suboptimal glycemic outcomes (glycated hemoglobin[HbA1c] of 7-14% and time in range [TIR] 70% and time below range<4% at 4 and 12 weeks post-randomization. Secondary efficacy endpoints comprise changes from baseline at weeks 4 and 12 in other glycemic metrics (including HbA1c, fasting glucose, 2-hour postprandial glucose, and additional CGM metrics), C-peptide, immune responses, infection markers, and gut microbiota composition. Changes from baseline at week 12 in serum metabolomic profiles will also be assessed, encompassing bile acids, short-chain fatty acids, and other related metabolites. Safety endpoints include the incidence of adverse events and serious adverse events. Discussion: Our findings will offer new insight into the feasibility and effects of oral yFMT in adult with T1DM and provide the necessary evidence to power a subsequent multicenter large-scale study. Exploratory biomarker analyses conducted within this study may further pave the way for future individualized microbiome–based therapeutics. Trial registration: Chinese Clinical Trial Registry identifier: ChiCTR2500111955 (November 7, 2025).
- 1 October 2025
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 317 (1) , e250026
Liver MRI–derived Proton Density Fat Fraction Predicts Diabetes Risk in Patients with Obesity: A Dose-Response Study
The liver MRI–derived proton density fat fraction (PDFF) independently predicted prediabetes and diabetes risk in patients with obesity, and the liver PDFF–dysglycemia relationship was partially mediated by liver enzymes.
- 1 October 2025
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 317 (1) , e250026
Liver MRI–derived Proton Density Fat Fraction Predicts Diabetes Risk in Patients with Obesity: A Dose-Response Study
The liver MRI–derived proton density fat fraction (PDFF) independently predicted prediabetes and diabetes risk in patients with obesity, and the liver PDFF–dysglycemia relationship was partially mediated by liver enzymes.